Related Experiment Video
Updated: Apr 28, 2026

Evaluation of Caspase Activation to Assess Innate Immune Cell Death
Published on: January 20, 2023
A novel inflammatory regulator TIPE2 inhibits TLR4-mediated development of colon cancer via caspase-8
Xue-Mei Li1, Jing-Ran Su2, Shi-Ping Yan1
1Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Aims:
TIPE2 is a novel inflammation regulator, and the role of TIPE2 in colitis-induced colon cancer is not clear. The aim of this study was to test whether TIPE2 inhibits TLR4 pathway in colon cancer patients and to explore potential mechanism of TIPE2 in colon cancer by caspase-8.
Methods:
Expression of TIPE2 and TLR4 in human colon cancer tissues and cell line HT-29 was detected by immunohistochemistry or real-time PCR. TIPE2 mRNA was suppressed by siRNA transfection and the transfection efficiency was proved by fluorescence microscopy and real-time PCR. TLR4 pathway was activated by treating the cells with 1 μg/ml LPS for 4 h. Caspase-8 activities were tested by colorimetric assay in four HT-29 cell groups.
Results:
TIPE2 was expressed in the cytoplasm of colon cancer tissues and HT-29 cells. TIPE2 expression was more pronounced in colon cancer tissues compared to normal controls and it was related with lymph node metastasis and Dukes stage of colon cancer. TIPE2 expression was positively correlated with that of TLR4 in colon cancer (r=0.7354). TIPE2 expression was knocked down successfully by siRNA transfection. Caspase-8 activity was elevated both in TIPE2 knockdown cells and in TLR4 activated cells compared to wild-type cells (P< 0.05). And the caspase-8 activity was further increased in TIPE2 knockdown cells after TLR4 was activated (P < 0.05).
Conclusion:
TIPE2 can inhibit caspase-8 activity in colon cancer cells. TIPE2 can regulate TLR4 inflammatory effect and inhibit further amplification of cascade reaction via caspase-8, which provides one new therapeutic target for clinical treatment schedule.
Insights
Tumor necrosis factor alpha-induced protein 8-like protein 2 (TIPE2) inhibits caspase-8 activity in colon cancer. TIPE2 regulates the Toll-like receptor 4 (TLR4) pathway, offering a new therapeutic target for colon cancer treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Tumor necrosis factor alpha-induced protein 8-like protein 2 (TIPE2) is an inflammation regulator.
- The role of TIPE2 in colitis-induced colon cancer remains unclear.
- Toll-like receptor 4 (TLR4) signaling is implicated in colon cancer development.
Purpose of the Study:
- To investigate whether TIPE2 inhibits the TLR4 pathway in colon cancer.
- To explore the mechanism of TIPE2 in colon cancer via caspase-8.
- To assess TIPE2 expression in human colon cancer tissues and cell lines.
Main Methods:
- Immunohistochemistry and real-time PCR were used to detect TIPE2 and TLR4 expression.
- TIPE2 was knocked down using siRNA in HT-29 colon cancer cells.
- TLR4 pathway activation and caspase-8 activity were measured.
Main Results:
- TIPE2 expression was elevated in colon cancer tissues and correlated with lymph node metastasis and Dukes stage.
- TIPE2 expression positively correlated with TLR4 expression (r=0.7354).
- TIPE2 knockdown and TLR4 activation both increased caspase-8 activity, with a further increase upon combined knockdown and activation.
Conclusions:
- TIPE2 inhibits caspase-8 activity in colon cancer cells.
- TIPE2 regulates the TLR4 inflammatory pathway, inhibiting amplification via caspase-8.
- TIPE2 presents a potential therapeutic target for colon cancer treatment.
Related Concept Videos
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Inflammatory Bowel Disease III: Crohn's Disease
MAPK Signaling Cascades

